Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP

Blood (2019) 134 (Supplement_1): 5598.

https://doi.org/10.1182/blood-2019-132087

Published: 2019

Journal Articles

Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma

Alfred L. Garfall, MD, Andrew Dougherty, Dan T. Vogl, MD, MSCE, Brendan M Weiss, MD, Adam D Cohen, MD, David L. Porter, MD, Una O'Doherty, MD, PhD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, Don L. Siegel, M.D., Ph.D.,, Edward A. Stadtmauer, MD

Blood (2013) 122 (21): 3354.

https://doi.org/10.1182/blood.V122.21.3354.3354

Published: 2013

Journal Articles

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Aziz Nazha, Dan T. Vogl, MD, MSCE, Una O'Doherty, MD, PhD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, Selina Luger, MD, David L. Porter, MD, Stephen J. Schuster, Marie Gardler, Mary Sell, Don L. Siegel, MD, PhD, BSc, Edward A Stadtmauer, MD

Blood (2010) 116 (21): 2252.

https://doi.org/10.1182/blood.V116.21.2252.2252

Published: 2010

Journal Articles

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Rebecca L. Olin, MD, David L. Porter, MD, Selina M. Luger, MD, Stephen J. Schuster, MD, Donald Tsai, MD, PhD, Sunita Nasta, MD, Alexander Perl, MD, Alison W. Loren, MD, Steven Goldstein, MD, Eli Glatstein, MD, Donald L. Siegel, MD, PhD, Dan T. Vogl, MD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, BSN, Edward A. Stadtmauer, MD

Blood (2005) 106 (11): 1170.

https://doi.org/10.1182/blood.V106.11.1170.1170

Published: 2005

Journal Articles

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Rebecca L. Olin, MD, Selina M. Luger, MD, David L. Porter, MD, Stephen J. Schuster, MD, Donald Tsai, MD, Phd, Sunita Nasta, MD, Alexander Perl, MD, Alison W. Loren, MD, Steven Goldstein, MD, Patricia Mangan, CRNP, Vicki Sherry, CRNP, Kathleen Cunningham, RN, Bob Sachs, Kim Hummel, Edward A. Stadtmauer, MD

Blood (2004) 104 (11): 5193.

https://doi.org/10.1182/blood.V104.11.5193.5193

Published: 2004

Journal Articles

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Margie Kasner, MD, Selina Luger, MD, Edward Stadtmauer, MD, Stephen Schuster, MD, Donald Tsai, MD, Sunita Nasta, MD, Alexander Perl, MD, Alison Loren, MD, Steven Goldstein, MD, Patricia Mangan, CRNP, Robert Sachs, Donald Seigel, MD, David Porter, MD

Blood (2004) 104 (11): 1872.

https://doi.org/10.1182/blood.V104.11.1872.1872

Published: 2004

NARROW

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Email alerts

ASH Publications

American Society of Hematology

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Stem Cell Mobilization With Plerixafor + G-CSF In Comparison To Cyclophosphamide + G-CSF and Time-To-Progression After Autologous Stem Cell Transplantation For Multiple Myeloma

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy for Relapsed Multiple Myeloma.

Pegfilgrastim Versus Filgrastim To Accelerate Hematopoietic Recovery after High Dose Melphalan and Autologous Hematopoietic Stem Cell Transplant (ASCT) for Multiple Myeloma.

Utility of Prophylactic Autologous Stem Cell Collection for Patients with Acute Myeloid Leukemia in First Remission.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only